Jefferies analyst Maury Raycroft reiterated a Buy rating on Sierra Oncology Inc (NASDAQ: SRRA) yesterday and set a price target of $4.29. The company’s shares closed on Friday at $2.05.
According to TipRanks.com, Raycroft is a 5-star analyst with an average return of 25.3% and a 57.9% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Atara Biotherapeutics, and Reata Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sierra Oncology Inc with a $4.29 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.09 and a one-year low of $1.41. Currently, Sierra Oncology Inc has an average volume of 476.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of patients with cancer. It engages in the business of researching, developing, and commercializing therapies for the treatment of patients with cancer. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.
